This will play a video - Resolute Onyx Zotarolimus-Eluting Coronary Stent System

CTO PERFORMANCE BACKED BY EVIDENCE



Resolute Onyx™
Zotarolimus-Eluting
Coronary Stent System

Important Safety Information   Indications, Safety, and Warnings

LEARN MORE
EXPLORE THE OPTIONS
SEE THE DATA
LEARN HOW
Resolute Onyx DES Platinum Iridium Core and Cobalt Alloy Shell

ADVANCED PERFORMANCE

Ready for your complex CTO cases, offering exceptional deliverability1 and enhanced visibility1 where and when you need it most.

Core Wire Technology — enabling thinner struts with enhanced radiopacity,1 achieved by incorporating a platinum iridium core within a cobalt alloy outer shell.

MORE OPTIONS TO TREAT

Generous 2.0-5.0 mm size matrix2,3 accommodating longer lesions in a broad range of vessel sizes.

Resolute Onyx DES size range: 2.0 mm to 5.75 mm
Perspective Study4: 183 Resolute ZES Cohort

BACKED BY CLINICAL EVIDENCE

Proven to perform in a real-world patient population with chronic total occlusions, Resolute DES demonstrated clinical and procedural outcomes.2

DOWNLOAD STUDY

MORE EVIDENCE

Examine 5-year safety and efficacy data for the Resolute Zotarolimus-Eluting stent.4

DOWNLOAD CTO ANALYSIS
Resolute Pooled CTO Analysis4: 436 CTO Group; 467 TO Group

SPECIALIZED CTO TRAINING

Education and training to optimally address your patients’ needs and advance your clinical practice.

CONTACT A REPRESENTATIVE

800-828-3103

RESOURCE ON FILE

DOWNLOAD BROCHURE

PRODUCT FEATURES

Resolute Onyx™ DES features excellent deliverability,1 visibility,1 and a generous size matrix2 — with demonstrated procedural success in challenging PCI cases.2

MORE ABOUT
RESOLUTE ONYX™ DES
1

Compared with Resolute Integrity™ DES in benchtop testing. Data on file at Medtronic. May not be indicative of clinical performance.

2

Resolute Onyx™ DES IFU.

3

The Resolute Onyx stents should not be expanded to a diameter beyond the maximum labeled diameter listed on the label per the IFU. Postdilatation required for overexpansion.

4

Yeh, et al. Five-Year Clinical Outcomes for Resolute Zotarolimus-Eluting Stents in Total Occlusions. Presented at TCT 2018.

 

©2019 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Further, Together are trademarks of Medtronic. ™*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution in the USA only.